header
Image from OpenLibrary

The effect of direct antiviral agents (DAAs) on extra- hepatic manifestations in chronic hepatitis (C) / Ahmed Hassan Ahmed Abdelhalim ; Supervised Ayman Yosry Abdelrehim , Aly Abdelaziz Gaballah , Naglaa Aly Zayed

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Ahmed Hassan Ahmed Abdelhalim , 2018Description: 122 P. : charts , facsimiles ; 25cmOther title:
  • تأثير مضادات الفيروسات المباشرة على أعراض خارج الكبد في المرضى المصابين بإلتهاب كبدي فيروسي - سي [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine Summary: Introduction Management of extra-hepatic manifestations (EHMs) of HCV with direct-acting antiviral agents (DAAs) is focused on viral eradication and clinical remission. Data concerning the clinical and immunologic outcomes of DAAs in HCV-related EHMs is scarce. Aim: To assess the safety and efficacy (clinical and virologic response) of different sofosbuvir (SOF)-based regimens in a cohort of chronic HCV patients with different extra-hepatic manifestations. Methods One hundred adult chronic HCV patients with different EHMs were recruited from Endemic Medicine Department, Cairo University, Gastroenterology and Hepatology Department, El-Agouza Police Hospital and The National Hepatology and Tropical Medicine Research Institute (NHTMRI), Egypt. Different SOF-based regimens were used; Group A (SOF-based DAAs combination, for 3 months, n=35); Group B (INF-free therapy with SOF plus (ribavirin) RBV for 6 months, n=23) and Group C (Pegylated-IFN/RBV plus SOF for 3 months, n=42). SVR 12; defined as negative HCV RNA at least 12 weeks after end of therapy and clinical response (partial response, PR complete response, CR)of EHMs were assessed.Results Overall SVR12 was 93% and CR was 89% in all studied groups and circulating cryoglobulins were significantly decreased with SVR12, p value 0.003. Both SVR12 and CR were significantly observed with IFN-free regimen p value, 0.004 rather than IFN-based, p value, 0.21
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.33.Ph.D.2018.Ah.E (Browse shelf(Opens below)) Not for loan 01010110076342000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.33.Ph.D.2018.Ah.E (Browse shelf(Opens below)) 76342.CD Not for loan 01020110076342000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine

Introduction Management of extra-hepatic manifestations (EHMs) of HCV with direct-acting antiviral agents (DAAs) is focused on viral eradication and clinical remission. Data concerning the clinical and immunologic outcomes of DAAs in HCV-related EHMs is scarce. Aim: To assess the safety and efficacy (clinical and virologic response) of different sofosbuvir (SOF)-based regimens in a cohort of chronic HCV patients with different extra-hepatic manifestations. Methods One hundred adult chronic HCV patients with different EHMs were recruited from Endemic Medicine Department, Cairo University, Gastroenterology and Hepatology Department, El-Agouza Police Hospital and The National Hepatology and Tropical Medicine Research Institute (NHTMRI), Egypt. Different SOF-based regimens were used; Group A (SOF-based DAAs combination, for 3 months, n=35); Group B (INF-free therapy with SOF plus (ribavirin) RBV for 6 months, n=23) and Group C (Pegylated-IFN/RBV plus SOF for 3 months, n=42). SVR 12; defined as negative HCV RNA at least 12 weeks after end of therapy and clinical response (partial response, PR complete response, CR)of EHMs were assessed.Results Overall SVR12 was 93% and CR was 89% in all studied groups and circulating cryoglobulins were significantly decreased with SVR12, p value 0.003. Both SVR12 and CR were significantly observed with IFN-free regimen p value, 0.004 rather than IFN-based, p value, 0.21

Issued also as CD

There are no comments on this title.

to post a comment.